Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings is supported by a healthy late-stage CRO demand backdrop, with management citing strong award growth, win rates, and RFP activity despite a modest slowdown in 3Q biotech funding. Net new business awards reached a record $873 million in 3Q, LTM awards rose 23.9% year over year, and consensus still implies about 5% revenue growth and 4.5% EBITDA growth off the current 2026 midpoint. The positive outlook is also reinforced by cancellations that remain within the normal 3% to 5% range and appear driven more by product failures, safety signals, and reprioritization than by funding pressure, while the $20 million Cincinnati expansion should add operating leverage over time.

Medpace Holdings is viewed negatively because its strong exposure to emerging biopharma and small-to-mid-sized customers creates outsized cyclicality, with funding stress already causing elevated cancellations despite long-term growth in the ~$28 billion addressable market. The company’s improving bookings, RFPs, and win rates are offset by concentration risk, as management indicated its top 5 customer revenue concentration was about 33% in 2Q, driven by a small number of large metabolic programs that could roll off and pressure 2027 revenue. Broader CRO industry risks, including regulatory changes, weak capital markets, M&A-driven program consolidation, and shifts toward internal R&D, further cloud the durability of Medpace’s growth and support a cautious stance.